Holen Sie sich die Stockscreener-App
1.535
70.19%
0.636
Schlusskurs vom Vortag:
$0.899
Offen:
$1
24-Stunden-Volumen:
93.71M
Relative Volume:
64.39
Marktkapitalisierung:
$12.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.72M
KGV:
-0.5816
EPS:
-2.6394
Netto-Cashflow:
$-6.25M
1W Leistung:
+49.27%
1M Leistung:
+5.52%
6M Leistung:
-36.25%
1J Leistung:
-31.70%
1-Tages-Spanne:
$0.9099
$1.78
1-Wochen-Bereich:
$0.72
$1.78
52-Wochen-Spanne:
$0.72
$2.9516
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.5319 | 7.50M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.60 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.33 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
837.67 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.52 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
368.65 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com
Edesa Biotech stock surges on positive Phase 3 trial data By Investing.com - Investing.com Canada
Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Edesa Biotech Reports Positive Phase 3 Paridiprubart Results - TipRanks
Edesa Biotech reports mortality reduction in phase 3 trial - Investing.com
Edesa Biotech reports additional results from phase 3 paridiprubart study - marketscreener.com
Edesa Biotech reports mortality reduction in phase 3 trial By Investing.com - Investing.com South Africa
Edesa Biotech shows significant 28-day mortality reduction in 278-patient Phase 3 study - TradingView
Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study - TradingView
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - One News Page
Update Recap: Can Edesa Biotech Inc expand into new marketsMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
Will Edesa Biotech Inc. stock benefit from infrastructure spending2025 Earnings Surprises & Accurate Technical Buy Alerts - mfd.ru
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Edesa Biotech, Inc. SEC 10-Q Report - TradingView
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results - Bitget
Edesa Biotech (Nasdaq: EDSA) widens loss as R&D spending climbs - Stock Titan
Edesa Biotech, Inc. Reports Q1 2026 Financial Results and Updates on Clinical Programs for EB06 and Paridiprubart - Quiver Quantitative
Canada's Edesa Biotech Q1 net loss widens - TradingView
Can Edesa Biotech Inc. expand into new markets2025 Technical Patterns & Expert Verified Movement Alerts - mfd.ru
Gains Recap: Does Edesa Biotech Inc have pricing power2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Bull Run: Does Edesa Biotech Inc have pricing powerBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Price Action: Is Edesa Biotech Incs growth already priced inJuly 2025 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Fed Meeting: Can Edesa Biotech Inc sustain earnings growth2025 Top Decliners & Growth Focused Entry Point Reports - baoquankhu1.vn
Bearish Setup: Is PennantPark Investment Corporation a play on infrastructure spendingWeekly Trend Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Buy Signal: Can Edesa Biotech Inc expand into new marketsWeekly Gains Summary & Entry Point Strategy Guides - baoquankhu1.vn
Energy Moves: Is Edesa Biotech Incs growth already priced inJuly 2025 Reactions & Smart Allocation Stock Tips - baoquankhu1.vn
Does Edesa Biotech Inc stock benefit from AI growthEarnings Overview Report & Safe Entry Trade Reports - baoquankhu1.vn
Shorts Report: Will Edesa Biotech Inc stock gain from government policiesMarket Risk Analysis & Accurate Intraday Trade Tips - Bộ Nội Vụ
Is Edesa Biotech Inc. stock positioned for digital transformationShare Buyback & Stepwise Trade Execution Plans - Улправда
Why Edesa Biotech Inc. stock could be next big winnerDaily Trainer Picks & quick comparison of popular models - Улправда
Is Edesa Biotech Inc. stock vulnerable to regulatory risksMarket Performance Recap & Free Reliable Trade Execution Plans - Улправда
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
Published on: 2026-01-06 14:04:13 - ulpravda.ru
Market Recap: How robust is Invesco Bloomberg Analyst Rating Improvers stock financial positionMarket Performance Recap & Long-Term Safe Investment Plans - moha.gov.vn
What is the fair value of Edesa Biotech Inc. stock nowForecast Cut & Community Trade Idea Sharing - Улправда
Is Edesa Biotech Inc. stock supported by strong fundamentals2025 AllTime Highs & Daily Technical Stock Forecast Reports - Улправда
Will Edesa Biotech Inc. stock recover faster than peersBond Market & Stepwise Swing Trade Plans - DonanımHaber
Diluted earnings per share (diluted EPS) of Edesa Biotech, Inc. – BOATS:EDSA - TradingView — Track All Markets
Why analysts remain bullish on Edesa Biotech Inc. stockGap Down & Breakout Confirmation Alerts - Улправда
S P Trends: Is Edesa Biotech Inc. stock supported by strong fundamentals2025 Retail Activity & Low Risk High Win Rate Stock Picks - Улправда
Zacks Small Cap Comments on Edesa Biotech Q1 Earnings - Defense World
Zacks Small Cap Forecasts Edesa Biotech FY2028 Earnings - Defense World
EDSA: Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026 - Zacks Small Cap Research
Edesa Biotech advances dermatology and respiratory programs in fiscal 2025 - MSN
Edesa Biotech Advances Dermatology and Respiratory Programs in Fiscal 2025 - TipRanks
Edesa Biotech increases at-the-market offering limit to $2.26 million - Investing.com
[8-K] Edesa Biotech, Inc. Reports Material Event | EDSA SEC FilingForm 8-K - Stock Titan
[424B5] Edesa Biotech, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Edesa Biotech, Inc. SEC 10-K Report - TradingView — Track All Markets
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.29%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):